<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03863379</url>
  </required_header>
  <id_info>
    <org_study_id>AFIAP2019-01</org_study_id>
    <nct_id>NCT03863379</nct_id>
  </id_info>
  <brief_title>Sarcopenic Obesity in Neurodisabilities</brief_title>
  <acronym>SarcObeNDS</acronym>
  <official_title>Sarcopenic Obesity in Neurodisabled People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dionyssiotis, Yannis, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dionyssiotis, Yannis, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the frequency and thresholds for sarcopenic obesity in neurodisabled persons and
      the fat and lean mass distribution based on various neurodisabilities
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fat and lean mass in neurodisabled</measure>
    <time_frame>an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of sarcopenic obesity</measure>
    <time_frame>an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body mass index correlation with fat mass and visceral fat</measure>
    <time_frame>an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Sarcopenic Obesity</condition>
  <condition>Spinal Cord Injuries</condition>
  <condition>Stroke</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Neurodisabled persons</arm_group_label>
    <description>Persons with various neurodisabilities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Able bodied persons</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>whole body DXA</intervention_name>
    <description>Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Neurodisabled persons</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Persons with neurodisability, men and women in comparison with able-bodied controls.
        Controls considered healthy after physical examination and comprehensive medical history
        review, which was free of any previous fracture ,endocrine or metabolic bone disease,
        malignancy, drug abuse, alcoholism and hepatic or renal disorders.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Persons with

          -  stroke / cerebrovascular disease

          -  traumatic brain injury

          -  multiple sclerosis

          -  spinal cord injuries (including spinal cord lesions i.e. myelopathies etc.)

        Exclusion Criteria:

        Persons with

          -  heterotopic ossifications,

          -  chronic administration of drugs, which promote fat increase

          -  chronic administration of drugs, which promote bone or muscle loss

          -  co-existing other diseases such as: endocrinopathies, muscular dystrophies,
             non-alcoholic fatty liver disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Rehabilitation Center EKA</name>
      <address>
        <city>Ilion</city>
        <state>Athens</state>
        <zip>13122</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <results_reference>
    <citation>Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev. 2017 May;35:200-221. doi: 10.1016/j.arr.2016.09.008. Epub 2016 Oct 1. Review.</citation>
    <PMID>27702700</PMID>
  </results_reference>
  <results_reference>
    <citation>Pelletier CA, Miyatani M, Giangregorio L, Craven BC. Sarcopenic Obesity in Adults With Spinal Cord Injury: A Cross-Sectional Study. Arch Phys Med Rehabil. 2016 Nov;97(11):1931-1937. doi: 10.1016/j.apmr.2016.04.026. Epub 2016 Jun 7.</citation>
    <PMID>27282328</PMID>
  </results_reference>
  <results_reference>
    <citation>Polyzos SA, Margioris AN. Sarcopenic obesity. Hormones (Athens). 2018 Sep;17(3):321-331. doi: 10.1007/s42000-018-0049-x. Epub 2018 Jul 16. Review.</citation>
    <PMID>30014320</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dionyssiotis, Yannis, M.D.</investigator_affiliation>
    <investigator_full_name>Yannis Dionyssiotis</investigator_full_name>
    <investigator_title>Consultant of 1st PRM Department National Rehabilitation Center EKA, Athens, Greece</investigator_title>
  </responsible_party>
  <keyword>Sarcopenia</keyword>
  <keyword>sarcopenic obesity</keyword>
  <keyword>stroke</keyword>
  <keyword>sci</keyword>
  <keyword>TBI</keyword>
  <keyword>MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

